Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials

Author:

Zhai Chunjuan1ORCID,Wang Fen2,Xu Ruie3,Sun Xia4,Ma Wenbin5,Wang Li1

Affiliation:

1. Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University , No. 324 Jingwu Road, Huaiyin District, 250021, Jinan, Shandong , China

2. Department of Infection Management, Weishan People’s Hospital , No. 10 Chenghou Road, Xiazhen Street, Weishan County, 277600, Jining, Shandong , China

3. Department of Respiratory, Heze Municipal Hospital , No. 2888 Caozou, Mudan District, 274031, Heze, Shandong , China

4. Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University , No. 324 Jingwu Road, Huaiyin District, 250021, Jinan, Shandong , China

5. School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine , No. 1166 Liutai Avenue, Wenjiang District, 611137, Chengdu, Sichuan , China

Abstract

Abstract Purpose Umeclidinium plus vilanterol (UMEC/VI) is an inhaled long-acting muscarinic antagonist/long-acting beta2-agonist (LAMA/LABA), recently approved as once-daily maintenance therapy for chronic obstructive pulmonary disease (COPD). This meta-analysis aims to assess the efficacy and safety of UMEC/VI compared with fluticasone propionate plus salmeterol (FP/SAL). Methods A systematic search was conducted by a trained medical research librarian across MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Chinese Biomedical Literature Database (CBM) for randomized controlled trials comparing UMEC/VI with FP/SAL in COPD patients. Two reviewers independently assessed the risk of bias and extracted data. The primary outcome was 0–24 h weighted mean (wm) forced expiratory volume in the first second (FEV1), trough FEV1. The secondary outcomes were other lung functions, symptoms, quality of life, and safety. Results Three studies with 2119 patients were included in the meta-analysis. UMEC/VI showed improvement in 0–24 h wm FEV1 (mean difference (MD) 0.08 L, 95% confidence interval (CI) 0.06 to 0.10, P < 0.01, moderate quality) and trough FEV1 (MD 0.09 L, 95% CI 0.07 to 0.11, P < 0.01, moderate quality) in comparison with FP/SAL. UMEC/VI statistically significantly improved all other lung functions compared with FP/SAL. However, there were no significant differences between UMEC/VI and FP/SAL in rescue-medication use, symptomatic endpoints, and health outcomes. UMEC/VI also demonstrated fewer drug-related adverse effects (risk ratio 0.47, 95% CI 0.27 to 0.82, P = 0.01, low quality). Conclusions UMEC/VI, when compared with FP/SAL, demonstrated significant improvements in lung functions with fewer drug-related adverse effects. However, the conclusion was limited by the scarcity of studies and long-term trials.

Publisher

Oxford University Press (OUP)

Reference29 articles.

1. Chronic obstructive pulmonary disease;Christenson;Lancet,2022

2. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017;GBD Chronic Respiratory Disease Collaborators;Lancet Respir Med,2020

3. Global health estimates: leading causes of death. Cause specific mortality, 2000–2019;WHO,2019

4. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease;Kelly;Expert Rev Clin Pharmacol,2014

5. Update on clinical aspects of chronic obstructive pulmonary disease;Celli;N Engl J Med,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3